Cover Image
市場調查報告書

妊娠毒血症:開發中產品分析

Pre-Eclampsia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200480
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
妊娠毒血症:開發中產品分析 Pre-Eclampsia - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 63 Pages
簡介

妊娠毒血症是高血壓及其他器官系統的損傷造成的併發症。症狀有強烈頭痛、尿排放量減少、噁心或嘔吐、肺水腫造成的呼吸急促、肝臟的功能障礙、腹上部痛(通常是右側肋骨下)等。

本報告提供妊娠毒血症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。。

簡介

  • 調查範圍

妊娠毒血症概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥開發企業

  • A1M Pharma AB
  • Alnylam Pharmaceuticals, Inc.
  • Glenveigh Medical, LLC
  • LFB S.A.
  • Pluristem Therapeutics Inc.
  • VG Life Sciences, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8426IDB

Summary

Global Markets Direct's, 'Pre-Eclampsia - Pipeline Review, H2 2016', provides an overview of the Pre-Eclampsia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pre-Eclampsia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia
  • The report reviews pipeline therapeutics for Pre-Eclampsia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pre-Eclampsia therapeutics and enlists all their major and minor projects
  • The report assesses Pre-Eclampsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pre-Eclampsia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pre-Eclampsia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pre-Eclampsia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pre-Eclampsia Overview
  • Therapeutics Development
    • Pipeline Products for Pre-Eclampsia - Overview
    • Pipeline Products for Pre-Eclampsia - Comparative Analysis
  • Pre-Eclampsia - Therapeutics under Development by Companies
  • Pre-Eclampsia - Therapeutics under Investigation by Universities/Institutes
  • Pre-Eclampsia - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Pre-Eclampsia - Products under Development by Companies
  • Pre-Eclampsia - Products under Investigation by Universities/Institutes
  • Pre-Eclampsia - Companies Involved in Therapeutics Development
    • A1M Pharma AB
    • Alnylam Pharmaceuticals, Inc.
    • Glenveigh Medical, LLC
    • LFB S.A.
    • Pluristem Therapeutics Inc.
    • VG Life Sciences, Inc.
  • Pre-Eclampsia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A1M-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALN-AGT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • antithrombin (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • digoxin immune fab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-PAD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RMC-035 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Apelin Receptor for Pre-Eclampsia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VG-1177 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pre-Eclampsia - Dormant Projects
  • Pre-Eclampsia - Product Development Milestones
    • Featured News & Press Releases
      • Mar 22, 2016: A1M Pharma finalizes drug candidate for treating pre-eclampsia and files for substance patent
      • Jan 14, 2016: St. John Hospital Enrolling Patients in Phase 3 Trial for Early Onset Pre-eclampsia
      • Jan 06, 2016: New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in Ameliorating Pre-eclampsia and Indicates Their Superiority Over Other Cells
      • Dec 31, 2015: U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem's PLX-PAD Cells for Treatment of Severe Pre-eclampsia
      • Sep 24, 2015: New clinical trial at SLU treats pre-eclampsia in second-trimester pregnancies
      • Sep 12, 2014: Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen for the Treatment of Hypertensive Disorders of Pregnancy, Including Pre-eclampsia
      • Sep 10, 2014: Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting
      • Jul 23, 2014: rEVO Biologics Announces Enrollment of First Patient in Phase 3 Trial of ATryn to Treat Early Onset Pre-eclampsia (PRESERVE-1)
      • Jul 08, 2014: Orphan Drug Designation Granted in Europe for A1M Pharma's Treatment for Pre-eclampsia
      • Mar 31, 2014: rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn in Early-Onset Pre-eclampsia
      • Feb 25, 2014: rEVO Biologics Announces the Submission of an IND for ATryn in Pre-eclampsia
      • Feb 20, 2014: Pluristem Submits FDA Orphan Drug Application for Pre-eclampsia
      • Nov 04, 2013: Safety of Pluristem's PLX Cells Demonstrated in Pre-Clinical Pregnancy Model
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pre-Eclampsia, H2 2016
  • Number of Products under Development for Pre-Eclampsia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Pre-Eclampsia - Pipeline by A1M Pharma AB, H2 2016
  • Pre-Eclampsia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
  • Pre-Eclampsia - Pipeline by Glenveigh Medical, LLC, H2 2016
  • Pre-Eclampsia - Pipeline by LFB S.A., H2 2016
  • Pre-Eclampsia - Pipeline by Pluristem Therapeutics Inc., H2 2016
  • Pre-Eclampsia - Pipeline by VG Life Sciences, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pre-Eclampsia - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Pre-Eclampsia, H2 2016
  • Number of Products under Development for Pre-Eclampsia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top